PRESCIENT THERAPEUTICS LIMITED - Announcements

Market Cap $32.21M Add to my watchlist

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PTX	June 2015 Appendix 4C - Quarterly	PRICE SENSITIVE	30/07/15	Share
PTX	IND for Phase 1b/2 Ovarian Cancer Trial Transferred to PTX	PRICE SENSITIVE	29/06/15	Share
PTX	Change in substantial holding		26/06/15	Share
PTX	Becoming a substantial holder		26/06/15	Share
PTX	Change of Director's Interest Notices x 2		26/06/15	Share
PTX	s708A Notice & Appendix 3B		23/06/15	Share
PTX	PTX Issues shares for Milestone 1 - Pathway Acquisition		23/06/15	Share
PTX	US FDA Reactivates PTX's IND for PTX-100 Breast Cancer Trial	PRICE SENSITIVE	10/06/15	Share
PTX	Appendix 3B		27/05/15	Share
PTX	Distinguished Moffitt Cancer Center Scientist Appointed CSO		26/05/15	Share
PTX	Edison Investment Research Initiates Coverage		30/04/15	Share
PTX	March 2015 Appendix 4C - Quarterly	PRICE SENSITIVE	29/04/15	Share
PTX	Prescient Appoints Chief Medical Officer		28/04/15	Share
PTX	Encouraging Pre-Clinical Data Presented at US Cancer Meeting	PRICE SENSITIVE	21/04/15	Share
PTX	Approval received to transfer IND Sponsorship for PTX-200	PRICE SENSITIVE	01/04/15	Share
PTX	Roth Conference Presentation		10/03/15	Share
PTX	PTX to Present at 27th Annual Roth Conference		03/03/15	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	27/02/15	Share
PTX	Prescient Therapeutics Granted Key U.S. Patents	PRICE SENSITIVE	23/02/15	Share
PTX	PTX Acquires Worldwide License for Cancer Biomarker p27	PRICE SENSITIVE	09/02/15	Share
PTX	Change of Company Secretary and Registered Office		03/02/15	Share
PTX	Appendix 3Ys		30/01/15	Share
PTX	December 2014 Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	Share

PTX June 2015 Appendix 4C - Quarterly
30/07/15	PRICE SENSITIVE	Share
PTX IND for Phase 1b/2 Ovarian Cancer Trial Transferred to PTX
29/06/15	PRICE SENSITIVE	Share
PTX Change in substantial holding
26/06/15		Share
PTX Becoming a substantial holder
26/06/15		Share
PTX Change of Director's Interest Notices x 2
26/06/15		Share
PTX s708A Notice & Appendix 3B
23/06/15		Share
PTX PTX Issues shares for Milestone 1 - Pathway Acquisition
23/06/15		Share
PTX US FDA Reactivates PTX's IND for PTX-100 Breast Cancer Trial
10/06/15	PRICE SENSITIVE	Share
PTX Appendix 3B
27/05/15		Share
PTX Distinguished Moffitt Cancer Center Scientist Appointed CSO
26/05/15		Share
PTX Edison Investment Research Initiates Coverage
30/04/15		Share
PTX March 2015 Appendix 4C - Quarterly
29/04/15	PRICE SENSITIVE	Share
PTX Prescient Appoints Chief Medical Officer
28/04/15		Share
PTX Encouraging Pre-Clinical Data Presented at US Cancer Meeting
21/04/15	PRICE SENSITIVE	Share
PTX Approval received to transfer IND Sponsorship for PTX-200
01/04/15	PRICE SENSITIVE	Share
PTX Roth Conference Presentation
10/03/15		Share
PTX PTX to Present at 27th Annual Roth Conference
03/03/15		Share
PTX Appendix 4D and Half Year Financial Report
27/02/15	PRICE SENSITIVE	Share
PTX Prescient Therapeutics Granted Key U.S. Patents
23/02/15	PRICE SENSITIVE	Share
PTX PTX Acquires Worldwide License for Cancer Biomarker p27
09/02/15	PRICE SENSITIVE	Share
PTX Change of Company Secretary and Registered Office
03/02/15		Share
PTX Appendix 3Ys
30/01/15		Share
PTX December 2014 Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	Share

REFRESH

First 2

(20min delay)
Last 4.0¢		Change 0.000(0.00%)		Mkt cap ! $32.21M

Open	High	Low	Value	Volume
4.0¢	4.1¢	4.0¢	$22.35K	558.4K

Buyers (Bids)

No.	Vol.	Price($)
6	221774	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.1¢	860576	3

View Market Depth

No.	Vol.	Price($)
1	249700	0.043
3	145000	0.042
6	477461	0.041
7	247800	0.040
3	130000	0.039

Price($)	Vol.	No.
0.046	99540	2
0.047	18686	2
0.048	200000	1
0.049	194091	3
0.050	427445	9

Last trade - 14.51pm 19/11/2024 (20 minute delay)


Last 4.0¢		Change 0.000 ( 1.27 %)
Open	High	Low	Volume
4.0¢	4.0¢	4.0¢	94998
Last updated 12.16pm 19/11/2024 ?

PTX (ASX) Chart